The global peptide therapeutics market is valued at $38.0 billion in 2023 and is expected to reach $106.0 billion by 2033, expanding at a 10.8% CAGR from 2023 to 2033.
Peptide therapeutics now account for 53.7% of the global drug discovery market, with the Asia Pacific region leading the way in peptide-based drugs. Peptide medicines have been used to treat metabolic illnesses for over a century. Peptide drugs have numerous advantages over tiny chemical compounds, resulting in high demand across geographies.
Request a Report Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1038
The market outlook for peptide therapeutics is highly positive in the coming years, owing to the benefits associated with their consumption as well as the product’s wide range of applications in pharmaceuticals and the biotechnology sector. Peptide therapeutics manufacturers have recognised the critical role that their product can play in meeting unmet medical needs. Furthermore, peptide therapeutics may be a better option than small molecule and biological therapeutics. All of these factors have contributed to an increase in research and investment in peptide drug recovery over the last ten years, which is expected to bode well for the market’s future prospects.
Again, rising rates of metabolic disorders and the high prevalence of cancer drive the demand for investments in peptide therapy research and development. These diseases are the leading cause of death and disability worldwide. As a result, there is a greater demand for peptide therapeutic development. Peptide-based drug delivery for cancer cells, combined with advancements in next-generation therapeutics, will presumably supplement peptide therapeutics’ market expansion. Furthermore, there is a surge in interest in therapeutic peptide research for commercial reasons. As a result, it is expected that peptide drug recovery will play an important role in the healthcare industry.
“Heightened application of peptides in the treatment of diabetes and cancer will likely augment the sales of peptide therapeutics in the global market over the forecast period,” says an FMI analyst.
Key Takeaways:
- The popularity of oral peptide-based drugs will create appealing market opportunities.
- Peptide-based therapeutics will gain traction in Cosmeceuticals.
- Government assistance to promote market growth in North America.
- The peptide therapeutics industry will find numerous lucrative opportunities in India.
- The parenteral route segment will continue to gain preference in terms of administration route during the assessment period.
Avail Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-1038
Competitive Landscape
Eli Lilly and Company, AstraZeneca plc, Merck & Co., Inc., Ipsen S.A, Novo Nordisk A/S, and Teva Pharmaceutical Industries Ltd., among others are some of the major players in the peptide therapeutics market that are profiled in the full version of the report.
Major players are focusing on market expansion activities in a moderately competitive market. These companies are involved in distribution agreements, white space exploration, and joint ventures. The more established companies are focusing on collaborating with local players to expand their production capacities and strengthen their regional presence.
More Insights into the Peptide Therapeutics Market Report
FMI’s most recent report provides an unbiased analysis of the global peptide therapeutics market, with historical data from 2014 to 2022 and forecast statistics from 2023 to 2033. To understand the global market potential, growth, and range, the market is segmented based on application (cancer, cardiovascular diseases, central nervous systems, metabolic disorders, infections, hematological disorders, gastrointestinal disorders, dermatology, respiratory disorders, acromegaly, other applications), route of administration (parenteral route of administration, mucosal route of administration, oral route of administration, transdermal route of administration), drug type (branded drugs, generic/ biosimilar drugs), and region.
According to the most recent FMI reports, the North American peptide therapeutics market is expected to dominate the market over the forecast period. The regional market is growing due to an increase in government investments as well as an increase in industry spending on research and development activities in peptide therapeutics. This market is further supported by the expansion of the target market in the United States. Because of the high prevalence of cancer and increased research and development activities, the US peptide therapeutics market is expected to grow rapidly over the forecast period.
The peptide therapeutics market in India is expected to grow significantly in the coming years. The increasing use of synthetic peptide drugs in India is expected to drive market growth in this region. Rising chronic illness incidences and an ageing population also contribute to market growth.
According to segmentation, the parenteral route of administration will continue to gain traction over the forecast period.
Customization Available@ https://www.futuremarketinsights.com/customization-available/rep-gb-1038
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs